60 patents
Page 3 of 3
Utility
Ras Inhibitors
6 May 21
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James CREGG, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Andreas BUCKL, John E. KNOX, Yang LIU
Filed: 4 Nov 20
Utility
Ras Inhibitors
6 May 21
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Adrian L. GILL, Elena S. KOLTUN, James CREGG, Andreas BUCKL, Anne V. EDWARDS, Christopher SEMKO, Micah James GLIEDT, John E. KNOX
Filed: 4 Nov 20
Utility
Ras Inhibitors
6 May 21
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Elena S. KOLTUN, James CREGG, Naing AAY, Andreas BUCKL, Adrian L. GILL, James AGGEN, G. Leslie BURNETT, Jennifer PITZEN, Daniel M. WHALEN, John E. KNOX, Yang LIU
Filed: 4 Nov 20
Utility
Identifying new therapeutic agents
27 Apr 21
Disclosed herein are methods for identifying novel drug candidates.
Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
Filed: 20 Dec 18
Utility
2,5-DISUBSTITUTED 3-METHYL Pyrazines and 2,5,6-TRISUBSTITUTED 3-METHYL Pyrazines As Allosteric SHP2 Inhibitors
8 Apr 21
The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
Elena S. KOLTUN, Kevin MELLEM, Adrian GILL, Gert KISS, Christopher SEMKO, Naing AAY, Andreas BUCKL, Ashutosh JOGALEKAR, Walter WON
Filed: 18 Jun 20
Utility
Rapamycin Analogs As Mtor Inhibitors
1 Apr 21
The present disclosure relates to mTOR inhibitors.
James Bradley AGGEN, Arun P. THOTTUMKARA, G. Leslie BURNETT, Micah James Evans GLIEDT, Gert KISS, Walter WON, Julie Chu-Li LEE, Adrian Liam GILL, Christopher SEMKO, Jennifer PITZEN, Gang WANG, Nidhi TIBREWAL
Filed: 30 Oct 19
Utility
Methods and reagents for analyzing protein-protein interfaces
16 Mar 21
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein.
Gregory L. Verdine, M. James Nichols, Sharon A. Townson, Uddhav Kumar Shigdel, Seung-Joo Lee, Dylan T. Stiles, Neville J. Anthony
Filed: 9 May 18
Utility
Compositions and methods for the production of compounds
2 Feb 21
The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or β-lactam compounds) with such nucleic acids, vectors, and/or host cells.
Brian R. Bowman, Joshua A. V. Blodgett, Gregory L. Verdine, Daniel C. Gray, Jay P. Morgenstern, Lucy Foulston, Keith Robison
Filed: 12 Apr 17
Utility
Polycyclic Compounds As Allosteric SHP2 Inhibitors
30 Dec 20
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease.
Elena S. KOLTUN, Naing N. AAY, Andreas BUCKL, Kevin T. MELLEM, Brian R. BLANK, Jennifer PITZEN, Gang WANG, Ashutosh S. JOGALEKAR, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Adrian Liam GILL, James Joseph CREGG
Filed: 10 Jun 20
Utility
SHP2 Inhibitor Compositions and Methods for Treating Cancer
25 Nov 20
The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.
Robert J. NICHOLS, Mark A. GOLDSMITH, Christopher SCHULZE, Jacqueline SMITH, David E. WILDES, Stephen KELSEY, Mallika SINGH
Filed: 4 Mar 20
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
4 Nov 20
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for ex ample through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250.
Gregory Lawrence VERDINE, Brian Roger BOWMAN, Mathew Edward SOWA, Joshua Alan Van Dyke BLODGETT, Keith Earl ROBISON, Dylan Talbot STILES, Jay Paul MORGENSTERN, Sharon Ann TOWNSON, Uddhav Kumar SHIGDEL
Filed: 1 Dec 19
Utility
Pyridine, Pyrazine, and Triazine Compounds As Allosteric SHP2 Inhibitors
28 Oct 20
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease.
Jie Jack LI, Elena S. KOLTUN, Adrian Liam GILL, Andreas BUCKL, Walter WON, Naing AAY, Kevin MELLEM, Christos TZITZILONIS, Ashutosh JOGALEKAR, James Joseph CREGG
Filed: 9 Apr 20
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
24 Jun 20
The disclosure features macrocyclic compounds, alone and in combination with other therapeutic agents, as well as pharmaceutical compositions and protein complexes thereof, capable of modulating biological processes including RAS and RAS-RAF inhibition, and their uses in the treatment of cancers.
Meizhong JIN, Nicholas PERL, Anna KOHLMANN, Ning YIN, Jason T. LOWE, Jae Young AHN, Mark Joseph MULVIHILL, Elena S. KOLTUN, Adrian L. GILL
Filed: 19 Dec 19
Utility
Compounds That Participate In Cooperative Binding and Uses Thereof
24 Jun 20
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein (e.g., a eukaryotic target protein such as a mammalian target protein or a fungal target protein or a prokaryotic target protein such as a bacterial target protein).
Mark Joseph MULVIHILL, Meizhong JIN
Filed: 3 Apr 18
Utility
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors
16 Mar 20
The present disclosure is directed to inhibitors of SHP2, such as pyrazine compounds, and their use in the treatment of disease associated with SHP2 modulation, such as Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia and cancers of the breast, lung and colon.
Elena S. Koltun, Kevin Mellem, Adrian Gill, Gert Kiss, Christopher Semko, Naing Aay, Andreas Buckl, Ashutosh Jogalekar, Walter Won
Filed: 19 Dec 18
Utility
Bicyclic Compounds As Allosteric SHP2 Inhibitors
15 Jan 20
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease.
Brian R. BLANK, Jennifer PITZEN, Gang WANG, Walter S. WON, Christos TZITZILONIS, Jie Jack LI, Elena S. KOLTUN, Naing AAY, Andreas BUCKL, Kevin MELLEM, Christopher SEMKO, Ash JOGALEKAR, Gert KISS, Adrian GILL
Filed: 21 Jul 19
Utility
Pyridine Compounds As Allosteric SHP2 Inhibitors
15 Jan 20
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease.
Adrian GILL, Naing AAY, Kevin MELLEM, Andreas BUCKL, Elena S. KOLTUN, Christopher SEMKO, Gert KISS
Filed: 21 Jul 19
Utility
Compounds that participate in cooperative binding and uses thereof
13 Jan 20
The invention features compounds (e.g., macrocyclic compounds) capable of modulating biological processes, for example through binding to a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein such as CEP250.
Gregory Lawrence Verdine, Brian Roger Bowman, Mathew Edward Sowa, Joshua Alan Van Dyke Blodgett, Keith Earl Robison, Dylan Talbot Stiles, Jay Paul Morgenstern, Sharon Ann Townson, Uddhav Kumar Shigdel
Filed: 7 Jan 16
Utility
C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
6 Nov 19
The present disclosure relates to mTOR inhibitors.
Jennifer Pitzen, Micah James Evans Gliedt, G. Leslie Burnett, James Bradley Aggen, Gert Kiss, James Joseph Cregg, Christopher Michael Semko, Walter Won, Gang Wang, Julie Chu-Li Lee, Arun P. Thottumkara, Adrian Liam Gill, Kevin T. Mellem
Filed: 28 Apr 19
Utility
Methods and reagents for analyzing protein-protein interfaces
4 Nov 19
The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the FKBP family, a member of the cyclophilin family, or PIN1) and a target protein.
Gregory L. Verdine, M. James Nichols, Sharon A. Townson, Uddhav Kumar Shigdel, Seung-Joo Lee, Dylan T. Stiles, Neville J. Anthony
Filed: 8 May 18